Centennial Investors invested more than $30 million in than 30+ startups. Follow on investments have been made in several of the portfolio companies. CI has enjoyed one successful total exit — Media Convergence Group (also known as Newsy). And two successful partial exits — Elemental Enzymes. CI members have lost their investments in six enterprises.
resistanceBio is a biopharma company dedicated to finding cures for drug-resistant cancers.
Mobility Design is the creator of the M+D Crutch. Through this initial product, and future product portfolio, they are transforming crutch-assisted mobility to become more comfortable and functional.
Healium is clinically validated mental fitness channel that uses virtual and augmented reality apps for self-management of stress and anxiety.
AdSwapper runs in the background of your phone, automatically filtering the ads in your apps and websites, and only letting through ads that will pay you.
The MIC Accelerator Fund provides early investment to selected companies who have a well-defined plan for a technology- based, market-changing product or service in the state of Missouri.
Elemental Enzymes is a manufacturer specialized in the production of enzymes specifically designed for survival and activity in harsh conditions.
Immunophotonics is engaged in the development of a proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine for the treatment of metastatic solid tumors.
Equinosis developed and sells worldwide an equine lameness detection and evaluation system. The Equinosis Q with Lameness Locator® is a veterinary diagnostic system used to objectively measure a horse’s movement.
Lending Standard has an enterprise underwriting platform that they sell to lenders in multi-family residential space. They leveraged their automated underwriting platform to originate loans for lenders. multifamilydebt.com
CryoCrate has a platform technology specializing in the cryopreservation of cells and tissue at -80c with no cell damage.
Antibiotic resistance causes over 700,000 deaths annually. Physicians want to use targeted antibiotics. Current methods to identify specific bacteria take days. The Acenxion Biosystem solution provides precise results in 4 – 6 hours.
Endevica Bio's technology platform allows the modification of peptides to perform better as drug candidates. The firm’s leading drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions.
Developing the next-generation trait delivery technology that harnesses the powerhouse of the cell – chloroplast – to efficiently build higher yielding food and feed crops.
Food crop insects are developing resistance to biotech crops and biopesticides. Impetus Ag is developing insect control products that protect crops without damaging the environment, people, or non-target insects.
Kremenak Nanotech has developed Urchin Black™ antimicrobial (UBam™), a platform coating material that physically shreds bacteria and fungi and immobilizes viruses.
ThermAvant Technologies® designs and manufactures high efficiency thermal - mechanical structures with the oscillating heat pipe (OHP) technology for aerospace, defense, and high-technology customers.